Company / Total Debt
Charles River Laboratories Total Debt History
FY2016-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$1.6B
FY2018
5-year range
-
FY2016-FY2018
Trend
+48.3%
vs FY2017
Sector context
#41 of 99
Health Care
What the data says
At $1.6B, Charles River Laboratories's total debt ranks #59 of 99 in the Health Care sector. Increased from $1.2B to $1.6B over the past 2 years.
Based on SEC 10-K filings.
$1.6B in FY2018.
Increased from $1.2B to $1.6B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#59 of 99 in Health CareTop 59% of 99This company $1.6B Sector average $4.6B
▼
-64.8% below sector average
Key checks
Key Insights
- In FY2018, total debt increased 48.3% year-over-year.
- Ranks #41 out of 99 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $1.6B | +48.3% |
| FY2017 | $1.1B | -8.0% |
| FY2016 | $1.2B | +45.0% |
As of FY2018 · SEC 10-K · Updated Jul 4, 2026